Auro Laboratories Limited

314,T.V.Industrial Estate, S.K.Ahire Marg
Worli,Mumbai – 400 030. India
Tel .: + 91 22 6663 5456
Fax : + 91 22 6663 5460
Email : auro@aurolabs.com
Web : www.aurolabs.com
Reg.Off / Mfg.Unit :
K-56, M.I.D.C. Tarapur,
Dist. Palghar, Maharashtra – 401506
CIN No. L33125MH1989PLC051910

Date: August 14, 2026

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

Ref: Security Code No./ISIN: 530233/ INE292C01011

Sub: Outcome of the meeting of Board of Directors dated August 14, 2026.

Dear Sir / Madam,

Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting to be held on **(i.e. Friday, August 14, 2026)**, has transacted the following business:

1. Approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2026 as recommended by the Audit Committee.

   In this regard, we are enclosing herewith:
   - Unaudited Financial Results for the quarter ended June 30, 2026.
   - Limited Review Report received from the Statutory Auditors of the Company.

The Meeting of the Board of Directors commenced at 03:30 p.m. and concluded at 04:30 p.m.

The results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in due course.

Kindly take the above information on records.

Thanking You,

Yours Faithfully,
For **AURO LABORATORIES LIMITED**

SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN: 00230796
Encl.: A/a

AURO LABORATORIES LIMITED

CIN NO. :- L33125MH1989PLC051910
Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR
BOISAR, DIST. PALGHAR 401506 , MAHARASHTRA
Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com

ANNEXURE - I

(Rs. In Lakhs except EPS)

PART-1: STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

Sr. No.	Particulars	Quarter Ended			Year Ended
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from Operations	876.81	983.25	277.42	3,073.98
2	Other Income	10.83	66.38	41.65	200.93
3	Total Income (1 + 2)	887.64	1,049.63	319.07	3,274.91
4	Expenses				
	a. Cost of raw material consumed	412.66	372.65	124.82	1,427.66
	b. Purchase of Stock-in-trade	1.50	0.00	-	1.43
	c. Changes in inventories of finished goods, work-in-progress and stock in trade	(241.67)	(168.90)	(34.77)	(823.00)
	d. Employee benefits expense	125.91	199.52	49.11	586.21
	e. Finance Cost	136.85	148.74	28.07	425.29
	f. Depreciation and amortisation expenses	91.36	90.35	27.41	281.02
	g. Other Expenses	247.99	247.33	134.97	881.07
	Total Expenses (4)	774.59	889.68	329.62	2,779.67
5	Profit / (Loss) before exceptional items and tax (3 ± 4)	113.05	159.95	(10.55)	495.23
6	Exceptional items	-	14.42	-	14.42
7	Profit / (Loss) before tax (5 ± 6)	113.05	145.53	(10.55)	480.82
8	Tax expense				
	(a) Current tax expenses for current year	-	-	-	-
	(b) Deferred tax	8.49	48.46	-	127.53
9	Profit / (Loss) for the period from continuing operation (7± 8)	104.56	97.07	(10.55)	353.29
10	Profit / (Loss) for discontinuing operations	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-
12	Profit / (Loss) for discontinuing operation (after tax) (10 ± 11)	-	-	-	-
13	Profit / (Loss) for the period (after tax) (9 ± 12)	104.56	97.07	(10.55)	353.29
14	Other Comprehensive Income				
	A. Items that will not be reclassifed subsequently to profit or loss				
	(i) Items that will not be reclassified to profit or loss	0.22	(0.13)	44.80	(15.96)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.03)	0.02	(11.28)	0.62
	B. Items that will be reclassifed subsequently to profit or loss	-	-	-	-
	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other comprehensive income /(loss), net of tax (14)	0.19	(0.11)	33.52	(15.34)
15	Total Comprehensive Income for the period [comprising Profit/(Loss) for the period (after tax) and other comprehensive income (after tax)] (13 ± 14)	104.75	96.96	22.97	337.95
16	Paid-up equity share capital (Face value of Rs. 10 each)	623.25	623.25	623.25	623.25
17	Other Equity	-	-	-	4,011.50
18	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares)				
	(a) Basic	1.68	1.56	(0.17)	5.67
	(b) Diluted	1.68	1.56	(0.17)	5.67

Notes on financial results:-

1 The Un-Audited Standalone Financial Results have been prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standards (IndAS 34), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI) under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, [SEBI (LODR) Regulations, 2015] as amended.

2 The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meeting held on 14th August,2026.

3 In accordance with Regulation 33 of the SEBI (LODR) Regulations, 2015, the above Un-Audited Standalone Financial Results of the Company are posted on Company's website (www.aurolabs.com) and on the website of BSE Limited (www.bseindia.com) where the Company's shares are listed.

4 The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind AS 108 on operating

5 The figures for the previous quarter ended 30th June,2025 were audited by the erstwhile auditors and the same has been relied upon.

6 Figures for the previous Period/ Year have been re-grouped/ reworked/ re-arranged wherever necessary, to make them comparable.

For and on behalf of the Board of Directors
Auro Laboratories Limited

AURO LABORATORIES LIMITED
MUMBAI
INDIA

Siddhartha Deorah
Whole Time Director
DIN: 00230796

Place: Mumbai
Dated : 14th August, 2026

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY UNAUDITED STANDALONE FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS,2015

Review Report to
The Board of Directors,
AURO LABORATORIES LTD,
Mumbai.

1) We have reviewed the accompanying Statement of Unaudited Standalone Financial Result of **Auro Laboratories Ltd** (''the Company'') for the quarter ended 30th June, 2026("the Statement"), being submitted by Company to the Stock Exchange viz. BSE Limited ("BSE") pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation"), read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated 29thMarch, 2019 ("the Circular").

2) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, "Interim Financial Reporting", (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

3) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of Entity "("the Standard"),* issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4) Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Regulation, read with the circular, including the manner in which it is to be disclosed or that it contains any material misstatement.

For B.L.Dasharda & Associates
Chartered Accountants
Firm Registration No. :112615W

B. L. DASHARDA & ASSOCIATES
MUMBAI
Firm Reg. No.
112615W
CAS

Sushant

CA Sushant Mehta
Partner
Membership No. :112489
Place: Mumbai
Date : 14th August, 2026
UDIN No: 26112489IKYAGS3755